Krishnansu Tewari, MD
Gynecologic Oncology · Orange, CANPI 1205868445
Payments from drug & device makers
Across 603 payments — averaging $5024.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Merck$1.3M
- Takeda Pharmaceuticals U.S.A., Inc.$653K
- Seagen Inc.$206K
- AstraZeneca$131K
- Eisai Inc.$104K
- Genentech, Inc.$93K
- plus $562K from 20 others
Across 33 payments — averaging $362.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Regeneron$9K
- AbbVie$3K
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Merck | 140 | $1,280,320 |
| Takeda Pharmaceuticals U.S.A., Inc. | 64 | $652,971 |
| Seagen Inc. | 32 | $206,444 |
| AstraZeneca | 73 | $130,768 |
| Eisai Inc. | 28 | $104,153 |
| Genentech, Inc. | 17 | $93,453 |
| Genmab U.S., Inc. | 21 | $82,353 |
| Tesaro, Inc. | 72 | $72,553 |
| GSK | 54 | $62,234 |
| Regeneron | 12 | $60,249 |
| Roche Products Limited | 18 | $56,919 |
| Karyopharm Therapeutics Inc. | 10 | $47,328 |
| Amgen | 4 | $41,503 |
| Blueprint Medicines Corporation | 4 | $36,148 |
| Corcept Therapeutics | 7 | $34,458 |
| Pfizer | 7 | $26,648 |
| Clovis Oncology, Inc. | 27 | $21,969 |
| Astrazeneca UK Limited | 2 | $4,110 |
| Aadi Bioscience, Inc. | 3 | $3,966 |
| Eisai CO., LTD. | 1 | $3,900 |
| EMD Serono, Inc. | 1 | $3,750 |
| Chugai Pharmaceutical Co., Ltd. | 1 | $3,040 |
| Myriad Genetic Laboratories, Inc. | 1 | $125 |
| Pacira Pharmaceuticals Incorporated | 1 | $105 |
| Dysis Medical, Inc. | 1 | $77 |
| AbbVie | 2 | $76 |
How this compares
$3,029,622 in reported general payments places this provider in the 95th percentile of 152 gynecologic oncology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other gynecologic oncology in Orange
- Philip DisaiaOrange$1.2M
- Fabio CappucciniOrange$1.1M
- Jill TsengOrange$128K
- Ramez EskanderEncinitas$8.2M
- John ChanSan Francisco$3.1M
- Dana ChaseLos Angeles$2.8M
- Edwin AlvarezSacramento$1.4M
- Alberto MendivilNewport Beach$1.2M
- Michael McHalela Jolla$979K
- Lee-May ChenSan Francisco$930K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.